Aarti Pharmalabs Limited · NSE:AARTIPHARM
Aarti Pharmalabs — FY2025 Earnings Presentation
29 slides from Aarti Pharmalabs's earnings presentation, May 12, 2025
Slide 1: Exchange filing cover letter: Results Presentation
May 12, 2025 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE LTD. National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, “Exchange Plaza”, Plot No. C/1, Mumbai - 400 001 G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 SCRIP CODE: 54374
Slide 2: Investor Presentation May 2025
INVESTOR PRESENTATION MAY 2025
Slide 3: Snapshot
SNAPSHOT 25 Years of Pharmaceutical Excellence 220+ Products 500+ Global Clients State-of-the-art 3 R&D facilities 58 Patents Filed 50+ Export Countries Manufacturing 6 Units 50 US DMF 2,100+ Employees 3 USFDA Units 31 CEP Global 15-20% Market Share 0.19x Net Debt/Equity A+ Credit rating in Xanthine
Slide 4: Company Overview
1 COMPANY OVERVIEW 2 BUSINESS OVERVIEW 3 STRATEGIC OVERVIEW 4 FINANCIAL OVERVIEW Aarti Pharmalabs Limited
Slide 5: Company Overview
COMPANY OVERVIEW STANDALONE REVENUE (INR Mn) • Aarti Pharmalabs Limited (APL) is part of the Aarti group – a diversified chemical conglomerate with & EBITDA MARGINS (%) group turnover of INR 130+ bn (FY25) 17,714 • Globally recognized manufacturer of generic API, Xanthine derivatives and a leading p
Slide 6: Key Milestones
KEY MILESTONES • 2024 Started 21 MW solar power project at Akola, Maharashtra • Expansion of semi-commercial production block at Vapi 2022 • Expanded block for CSD in Vapi and API in Tarapur units • Acquired land at Atali for future growth 12 • Successfully demerged the pharmaceutical business of Aa
Slide 7: Geographical Presence
GEOGRAPHICAL PRESENCE Atali Vapi - Unit II Tarapur - Unit III, IV, V, VI Dombivli - Unit I Gujarat Mumbai Maharashtra LOCATION MANUFACTURING UNITS CERTIFICATIONS & AUDIT DATE Dombivali Unit - I (API, Intermediates, CDMO) USFDA - Jun 2022 Unit - II (API, Intermediates, CDMO) Vapi USFDA - Sep 2009, Au
Slide 8: Manufacturing Capabilities
MANUFACTURING CAPABILITIES END TO END CAPABILITIES UNDER ONE UMBRELLA Hydrogenation facilities from lab-scale to 25 years of experience in pharmaceuticals manufacturing scale (0.1-10 KL reactors) manufacturing for global clients Impeccable regulatory track record and facilities Cryogenic reactors op
Slide 9: Research & Development
RESEARCH & DEVELOPMENT 3 40+70+ 3 State of the art Products developed and R&D Centers at manufactured on kilo-lab Maharashtra & Gujarat scale in FY25 25+ 5% 70+ 3 17 3 New products R&D Spend (as a PhDs launched at plant scale percent of API+Int & in FY25 CDMO sales ) in FY25 110 3 42 Cr70+ 3 55 70+
Slide 10: Business Overview
1 COMPANY OVERVIEW 2 BUSINESS OVERVIEW 3 STRATEGIC OVERVIEW 4 FINANCIAL OVERVIEW Aarti Pharmalabs Limited
Slide 11: Key Business Segments
KEY BUSINESS SEGMENTS QUARTERLY REVENUE BREAK-UP 34.3% 43.5% 52.6% Xanthine Derivatives & Allied Products 38.8% API & Intermediates 43.6% 36.1% 26.9% CDMO/CMO 11.3% 12.9% FY24 FY25 Q4-FY25 CDMO/CMO API & Intermediates Xanthine derivatives
Slide 12: Xanthine Derivatives & Allied Products
XANTHINE DERIVATIVES & ALLIED PRODUCTS • Largest Indian manufacturer of Xanthine Derivatives, including Caffeine (largest capacity in India), SALES QUANTITY SPLIT (FY25) Theophylline Anhydrous, Aminophylline, Etophylline, and Theophylline • Non-Chinese dependent and fully backward integrated manufac
Slide 13: API & Intermediates
API & INTERMEDIATES • Specialized player in the development and manufacturing of HPAPIs, catering to the demand for critical drugs used in oncology, corticosteroids, and cytotoxic medicines. MARKET SEGMENTATION (FY25) • Backward integrated for most APIs, with control over entire production value cha
Slide 14: CDMO & CMO
CDMO & CMO • Amongst leading small molecule CDMO/CMO players in India, working with big pharma, innovators CDMO Sales (INR Cr) and biotech companies. • Offering end to end services including process development and manufacturing of KSMs, RSMs, Intermediates & GMP APIs for small molecule NCEs, from e
Slide 15: Strategic Overview
1 COMPANY OVERVIEW 2 BUSINESS OVERVIEW 3 STRATEGIC OVERVIEW 4 FINANCIAL OVERVIEW Aarti Pharmalabs Limited
Slide 16: Growth Drivers & Outlook
GROWTH DRIVERS & OUTLOOK Strong pipeline of new products in API & Intermediates business Fortify market leading CDMO & CMO business position in the Xanthine growing strong with segment by ongoing estimated sales increase of brownfield capacity 30-40% YoY in FY26 expansion to 9000+ MTPA 4 Adding 450+
Slide 17: Financial Overview
1 COMPANY OVERVIEW 2 BUSINESS OVERVIEW 3 STRATEGIC OVERVIEW 4 FINANCIAL OVERVIEW Aarti Pharmalabs Limited
Slide 18: Quarterly Consolidated Income Statement
QUARTERLY CONSOLIDATED INCOME STATEMENT PARTICULARS (INR Mn) Q4-FY25 Q3-FY25 Q-O-Q Q4-FY24 Y-O-Y Operational Revenue 5,638 5,378 4.8% 5,058 11.5% Operating Expenses 4,182 4,092 2.2% 3,883 7.7% EBITDA 1,456 1,286 13.2% 1,175 23.9% EBITDA Margin (%) 25.82% 23.91% 191 Bps 23.23% 259 Bps Depreciation an
Slide 19: Annual Consolidated Income Statement
ANNUAL CONSOLIDATED INCOME STATEMENT PARTICULARS (INR Mn) FY25 FY24 Y-O-Y Operational Revenue 21,151 18,526 14.2% Operating Expenses 16,507 14,666 12.6% EBITDA 4,644 3,860 20.3% EBITDA Margin (%) 21.96% 20.84% 112 Bps Depreciation and Amortisation 869 732 18.7% Finance costs 269 172 56.4% Other Inco
Slide 20: Historical Consolidated Income Statement
HISTORICAL CONSOLIDATED INCOME STATEMENT PARTICULARS (INR Mn) 9M-FY22 FY23 FY24 FY25 Operational Revenue 11,999 19,452 18,526 21,151 Total Expenses 9,929 16,031 14,666 16,507 EBITDA 2,070 3,421 3,860 4,644 EBITDA Margins (%) 17.25% 17.59% 20.84% 21.96% Depreciation and Amortisation 421 625 732 869 F
Slide 21: Quarterly Standalone Income Statement
QUARTERLY STANDALONE INCOME STATEMENT PARTICULARS (INR Mn) Q4-FY25 Q3-FY25 Q-O-Q Q4-FY24 Y-O-Y Operational Revenue 5,296 4,709 12.5% 4,148 27.7% Operating Expenses 3,865 3,559 8.6% 3,075 25.7% EBITDA 1,431 1,150 24.4% 1,073 33.4% EBITDA Margin (%) 27.02% 24.42% 260 Bps 25.87% 115 Bps Depreciation an
Slide 22: Annual Standalone Income Statement
ANNUAL STANDALONE INCOME STATEMENT PARTICULARS (INR Mn) FY25 FY24 Y-O-Y Operational Revenue 17,714 15,021 17.9% Operating Expenses 13,449 11,560 16.3% EBITDA 4,265 3,461 23.2% EBITDA Margin (%) 24.08% 23.04% 104 Bps Depreciation and Amortisation 791 660 19.8% Finance costs 256 166 54.2% Other Income
Slide 23: Historical Standalone Income Statement
HISTORICAL STANDALONE INCOME STATEMENT PARTICULARS (INR Mn) 9M-FY22 FY23 FY24 FY25 Operational Revenue 9,410 15,112 15,021 17,714 Total Expenses 7,613 12,028 11,560 13,449 EBITDA 1,797 3,084 3,461 4,265 EBITDA Margins (%) 19.10% 20.41% 23.04% 24.08% Depreciation and Amortisation 372 558 660 791 Fina
Slide 24: Historical Consolidated Balance Sheet
HISTORICAL CONSOLIDATED BALANCE SHEET ASSETS (INR Mn) FY22 FY23 FY24 FY25 EQUITY & LIABILITIES (INR Mn) FY22 FY23 FY24 FY25 Non-current assets Equity share capital 3 453 453 453 Property, plant and equipment 7,777 9,227 9,942 10,887 Equity Share Capital Pending 453 - Capital work-in-progress 1,652 6
Slide 25: Historical Standalone Balance Sheet
HISTORICAL STANDALONE BALANCE SHEET ASSETS (INR Mn) FY22 FY23 FY24 FY25 EQUITY & LIABILITIES (INR Mn) FY22 FY23 FY24 FY25 Assets Equity & Liabilities Non-current assets Equity share capital 3 453 453 453 Property, plant and equipment 6,985 8,471 9,160 10,135 Equity Share Capital Pending Capital work
Slide 26: Consolidated Financial Highlights
CONSOLIDATED FINANCIAL HIGHLIGHTS OPERATIONAL INCOME (INR Mn) EBITDA (INR Mn) & EBITDA PAT (INR Mn) & PAT MARGINS (%) MARGINS (%) 4,644 21,151 19,452 3,860 2,724 18,526 3,421 2,169 1,935 11,999 2,070 1,223 20.84% 21.96% 17.25% 17.59% 12.88% 10.19% 11.71% 9.95% 9M-FY22 FY23 FY24 FY25 9M-FY22 FY23 FY2
Slide 27: Capital Market Information
CAPITAL MARKET INFORMATION SHARE PRICE UP TO 31st MARCH, 2025 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% -10% Apr-24 May-24 Jun-24 Jul-24 Aug-24 Sep-24 Oct-24 Nov-24 Dec-24 Jan-25 Feb-25 Mar-25 AARTIPHARM Sensex PRICE DATA (AS ON 31st MARCH, 2025) INR SHAREHOLDING PATTERN (AS ON 31st MARCH, 2025) DII, 7
Slide 28: Disclaimer
DISCLAIMER Aarti Pharmalabs Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all event
Slide 29: Thank You
THANK YOU AARTI PHARMALABS LIMITED